sorafenib has been researched along with erucin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (erucin) | Trials (erucin) | Recent Studies (post-2010) (erucin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 62 | 2 | 48 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erlacher, M; Hertrampf, A; Herz, C; Kleinhans, C; Lamy, E; Mersch-Sundermann, V; Platz, S; Rohn, S; Schüler, J; Stetter, N; Wagner, M; Zimmermann, S | 1 |
1 other study(ies) available for sorafenib and erucin
| Article | Year |
|---|---|
The isothiocyanate erucin abrogates telomerase in hepatocellular carcinoma cells in vitro and in an orthotopic xenograft tumour model of HCC.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Damage; Gene Expression; Hep G2 Cells; Humans; Immunoblotting; Isothiocyanates; Kidney; Liver; Liver Neoplasms; Mice, Nude; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Telomerase; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2014 |